Advertisement

Atrial Fibrillation in Heart Failure

Focus on Antithrombotic Management

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Cardiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Savarese G.
        • Lund L.H.
        Global public health burden of heart failure.
        Card Fail Rev. 2017; 3: 7
        • Anter E.
        • Jessup M.
        • Callans D.J.
        Atrial fibrillation and heart failure: treatment considerations for a dual epidemic.
        Circulation. 2009; 119: 2516-2525
        • Lloyd-Jones D.M.
        • Wang T.J.
        • Leip E.P.
        • et al.
        Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.
        Circulation. 2004; 110: 1042-1046
        • Chao T.
        • Liu C.
        • Tuan T.
        • et al.
        Lifetime risks, projected numbers, and adverse outcomes in asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF cohort study.
        Chest. 2018; 153: 453-466
        • Lip G.
        • Freedman B.
        • De Caterina R.
        • et al.
        Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making.
        Thromb Haemost. 2017; 117: 1230-1239
        • Lamassa M.
        • Di Carlo A.
        • Pracucci G.
        • et al.
        Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).
        Stroke. 2001; 32: 392-398
        • Thygesen S.K.
        • Frost L.
        • Eagle K.A.
        • et al.
        Atrial fibrillation in patients with ischemic stroke: A population-based study.
        Clin Epidemiol. 2009; 1: 55-65
        • Mackenzie J.
        Disease of the heart.
        3rd edition. Oxford Medical Publications, London1914
        • Ferreira J.P.
        • Santos M.
        Heart failure and atrial fibrillation: from basic science to clinical practice.
        Int J Mol Sci. 2015; 16: 3133-3147
        • Santhanakrishnan R.
        • Wang N.
        • Larson M.G.
        • et al.
        Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction.
        Circulation. 2016; 133: 484-492
        • Ling L.
        • Kistler P.M.
        • Kalman J.M.
        • et al.
        Comorbidity of atrial fibrillation and heart failure.
        Nat Rev Cardiol. 2016; 13: 131-147
        • Borre E.D.
        • Goode A.
        • Raitz G.
        • et al.
        Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review.
        Thromb Haemost. 2018; 118: 2171-2187
        • Lip G.Y.
        • Wrigley B.J.
        • Pisters R.
        Anticoagulation versus placebo for heart failure in sinus rhythm.
        Cochrane Database Syst Rev. 2012; (CD003336)https://doi.org/10.1002/14651858.CD003336.pub2
        • Lip G.Y.H.
        • Nieuwlaat R.
        • Pisters R.
        • et al.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
      1. Overview | Atrial fibrillation: management | Guidance | NICE.
        (Available at:) (Accessed February 28, 2019)
        • Lip G.Y.H.
        • Banerjee A.
        • Boriani G.
        • et al.
        Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report.
        Chest. 2018; 154: 1121-1201
        • Proietti M.
        • Mujovic N.
        • Potpara T.S.
        Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision.
        Thromb Haemost. 2018; 118: 2014-2017
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Balasubramaniam R.
        • Kistler P.M.
        Atrial fibrillation in heart failure: the chicken or the egg?.
        Heart. 2009; 95: 535-539
        • Clark D.M.
        • Plumb V.J.
        • Epstein A.E.
        • et al.
        Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation.
        J Am Coll Cardiol. 1997; 30: 1039-1045
        • Lee Park K.
        • Anter E.
        Atrial fibrillation and heart failure: a review of the intersection of two cardiac epidemics.
        J Atrial Fibrillation. 2013; 6: 751
        • Shinbane J.S.
        • Wood M.A.
        • Jensen D.N.
        • et al.
        Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies.
        J Am Coll Cardiol. 1997; 29: 709-715
        • Wang T.J.
        • Larson M.G.
        • Levy D.
        • et al.
        Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.
        Circulation. 2003; 107: 2920-2925
        • Gronefeld G.C.
        • Hohnloser S.H.
        Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications.
        J Cardiovasc Pharmacol Ther. 2003; 8: 107-113
        • Miyasaka Y.
        • Barnes M.E.
        • Gersh B.J.
        • et al.
        Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades.
        Eur Heart J. 2006; 27: 936-941
        • Melenovsky V.
        • Hwang S.
        • Redfield M.M.
        • et al.
        Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction.
        Circ Heart Fail. 2015; 8: 295-303
        • Zile M.R.
        • Gottdiener J.S.
        • Hetzel S.J.
        • et al.
        Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction.
        Circulation. 2011; 124: 2491-2501
        • Shah A.M.
        • Shah S.J.
        • Anand I.S.
        • et al.
        Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
        Circ Heart Fail. 2014; 7: 104-115
        • Cioffi G.
        • Gerdts E.
        • Cramariuc D.
        • et al.
        Left atrial size and force in patients with systolic chronic heart failure: Comparison with healthy controls and different cardiac diseases.
        Exp Clin Cardiol. 2010; 15: e45
        • Hartupee J.
        • Mann D.L.
        Neurohormonal activation in heart failure with reduced ejection fraction.
        Nat Rev Cardiol. 2017; 14: 30-38
        • Masuda M.
        • Yamada T.
        • Mizuno H.
        • et al.
        Impact of atrial fibrillation ablation on cardiac sympathetic nervous system in patients with and without heart failure.
        Int J Cardiol. 2015; 199: 65-70
        • Florea V.G.
        • Cohn J.N.
        The autonomic nervous system and heart failure.
        Circ Res. 2014; 114: 1815-1826
        • Floras J.S.
        • Ponikowski P.
        The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.
        Eur Heart J. 2015; 36: 1982b
        • Ng J.
        • Villuendas R.
        • Cokic I.
        • et al.
        Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation.
        Circ Arrhythm Electrophysiol. 2011; 4: 388-396
        • Antoine S.
        • Vaidya G.
        • Imam H.
        • et al.
        Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system.
        Am J Med Sci. 2017; 353: 27-30
        • Perera R.K.
        • Sprenger J.U.
        • Steinbrecher J.H.
        • et al.
        Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy.
        Circ Res. 2015; 116: 1304-1311
        • Khan A.A.
        • Lip G.Y.H.
        The prothrombotic state in atrial fibrillation: pathophysiological and management implications.
        Cardiovasc Res. 2019; 115: 31-45
        • Watson T.
        • Shantsila E.
        • Lip G.Y.H.
        Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.
        Lancet. 2009; 373: 155-166
        • Jafri S.M.
        • Ozawa T.
        • Mammen E.
        • et al.
        Platelet function, thrombin and fibrinolytic activity in patients with heart failure.
        Eur Heart J. 1993; 14: 205-212
        • Abe Y.
        • Asakura T.
        • Gotou J.
        • et al.
        Prediction of embolism in atrial fibrillation: classification of left atrial thrombi by transesophageal echocardiography.
        Jpn Circ J. 2000; 64: 411-415
        • Lip G.Y.
        Does atrial fibrillation confer a hypercoagulable state?.
        Lancet. 1995; 346: 1313-1314
        • Lip G.Y.
        • Lowe G.D.
        • Rumley A.
        • et al.
        Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
        Br Heart J. 1995; 73: 527-533
        • Mazurek M.
        • Huisman M.
        • Rothman K.
        • et al.
        Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry.
        Thromb Haemost. 2017; 117: 2376-2388
        • Triposkiadis F.
        • Pieske B.
        • Butler J.
        • et al.
        Global left atrial failure in heart failure.
        Eur J Heart Fail. 2016; 18: 1307-1320
        • Mountantonakis S.E.
        • Grau-Sepulveda M.V.
        • Bhatt D.L.
        • et al.
        Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure.
        Circ Heart Fail. 2012; 5: 191-201
        • Mamas M.A.
        • Caldwell J.C.
        • Chacko S.
        • et al.
        A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure.
        Eur J Heart Fail. 2009; 11: 676-683
        • Wasywich C.A.
        • Pope A.J.
        • Somaratne J.
        • et al.
        Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis.
        Intern Med J. 2010; 40: 347-356
        • Balsam P.
        • Gawałko M.
        • Peller M.
        • et al.
        Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study.
        Medicine (Baltimore). 2018; 97: e13074
        • Melgaard L.
        • Gorst-Rasmussen A.
        • Lane D.A.
        • et al.
        Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation.
        JAMA. 2015; 314: 1030-1038
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • et al.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Lip G.Y.H.
        • Lane D.A.
        Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores.
        J Thromb Haemost. 2016; 14: 1711-1714
        • Apostolakis S.
        • Lane D.A.
        • Buller H.
        • et al.
        Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
        Thromb Haemost. 2013; 110: 1074-1079
        • Sobue Y.
        • Watanabe E.
        • Lip G.Y.H.
        • et al.
        Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
        Heart Vessels. 2018; 33: 403-412
        • Brouwers F.P.
        • de Boer R.A.
        • van der Harst P.
        • et al.
        Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
        Eur Heart J. 2013; 34: 1424-1431
        • Zakeri R.
        • Chamberlain A.M.
        • Roger V.L.
        • et al.
        Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.
        Circulation. 2013; 128: 1085-1093
        • Sartipy U.
        • Dahlström U.
        • Fu M.
        • et al.
        Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction.
        JACC Heart Fail. 2017; 5: 565-574
        • Siller-Matula J.M.
        • Pecen L.
        • Patti G.
        • et al.
        Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF-HF substudy.
        Int J Cardiol. 2018; 265: 141-147
        • Kotecha D.
        • Chudasama R.
        • Lane D.A.
        • et al.
        Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes.
        Int J Cardiol. 2016; 203: 660-666
        • Zafrir B.
        • Lund L.H.
        • Laroche C.
        • et al.
        Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
        Eur Heart J. 2018; 39: 4277-4284
        • Guttmann O.P.
        • Rahman S.
        • O'Mahony C.
        • et al.
        Systematic review of atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy.
        Eur Heart J. 2013; 34https://doi.org/10.1093/eurheartj/eht309.P2965
        • Jung H.
        • Yang P.
        • Sung J.
        • et al.
        Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study.
        Thromb Haemost. 2019; 119: 285-293
        • Borer J.S.
        • Atar D.
        • Marciniak T.
        • et al.
        Atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy: important new insights.
        Thromb Haemost. 2019; 119: 355-357
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146 (Available at:) (Accessed February 28, 2019): 857-867
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Connolly S.
        • Ezekowitz M.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139
        • Xiong Q.
        • Lau Y.C.
        • Senoo K.
        • et al.
        Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
        Eur J Heart Fail. 2015; 17: 1192-1200
        • McMurray J.J.V.
        • Ezekowitz J.A.
        • Lewis B.S.
        • et al.
        Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
        Circ Heart Fail. 2013; 6: 451-460
        • Savarese G.
        • Giugliano R.P.
        • Rosano G.M.C.
        • et al.
        Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis.
        JACC Heart Fail. 2016; 4: 870-880
        • Magnani G.
        • Giugliano R.P.
        • Ruff C.T.
        • et al.
        Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
        Eur J Heart Fail. 2016; 18: 1153-1161
        • Ahmad Y.
        • Lip G.Y.H.
        • Apostolakis S.
        New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation.
        Expert Rev Cardiovasc Ther. 2012; 10: 1471-1480
        • Nielsen P.B.
        • Lane D.A.
        • Rasmussen L.H.
        • et al.
        Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
        Clin Res Cardiol. 2015; 104: 418-429
        • Jung H.
        • Yang P.
        • Jang E.
        • et al.
        Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study.
        Chest. 2019; 155: 354-363